Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Purchases $11,080.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson acquired 800 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $13.85 per share, with a total value of $11,080.00. Following the completion of the transaction, the vice president now directly owns 263,148 shares in the company, valued at approximately $3,644,599.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jaye Thompson also recently made the following trade(s):

• On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $15.15 per share, with a total value of $15,150.00.
• On Thursday, July 18th, Jaye Thompson purchased 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $16.00 per share, for a total transaction of $16,000.00.

Greenwich LifeSciences Trading Up 6.6 %

Shares of NASDAQ GLSI opened at $15.92 on Monday. The stock has a market capitalization of $205.05 million, a PE ratio of -22.11 and a beta of 1.61. Greenwich LifeSciences, Inc. has a twelve month low of $7.58 and a twelve month high of $21.44. The stock has a fifty day simple moving average of $14.68 and a 200-day simple moving average of $15.10.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). On average, equities analysts predict that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.

Institutional Investors Weigh In On Greenwich LifeSciences

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers purchased a new position in Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp purchased a new stake in shares of Greenwich LifeSciences during the second quarter worth $264,000. Finally, Vanguard Group Inc. raised its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.